ArticleJournal of experimental & clinical cancer research : CR2023

MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.

Jasmine Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.